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ABSTRACT 
A series of eighteen derivatives of marine sesquiterpene quinone avarone and its model system 
tert-butylquinone with amino acids has been synthesized by nucleophilic addition of amino acids 
to the quinones. In vitro cytotoxic activity toward human cancer cell lines (HeLa, A549, Fem-X, 
K562, MDA-MB-453) and normal MRC-5 cell line was determined. Several compounds showed 
very strong inhibitory activity with IC50 values less than 10 μM. Avarone derivatives were more 
active than the corresponding tert-butylquinone derivatives. The results of the cytofluorimetric 
analysis of cell cycle of HeLa cells showed that apoptosis might be one of possible mechanism 
of action of these compounds in cancer cells. In order to examine the influence of caspases on 
cell death, the apoptotic mechanisms induced by the tested compounds were determined using 
specific caspases 3, 8 and 9 inhibitors. For all compounds antibacterial activities against six 
strains of Gram-positive and four strains of Gram-negative bacteria were determined, as well as 
antifungal activity against three fungal species.  
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1. Introduction 
Marine organisms represent a rich source of metabolites with a high pharmacological 
potential and exceptionally different structures [1-4]. Many natural products with a decalin-type 
system and a quinoid moiety are important compounds with powerful and diverse biological 
properties [5-7]. 
Sponges of the order Dictyoceratida are a rich source of bioactive secondary metabolites, 
sesquiterpene quinones and hydroquinones such as avarol, avarone, illimaquinone, nakijiquinone 
and bolinaquinone. These compounds have attracted considerable interest due to their 
remarkable biological activities - antiproliferative, cytotoxic, antiviral and antimicrobial 
properties. All the above features of marine products provide the possibility for the further 
development of new agents which can be successfully identified as new drugs and/or factors 
which participate in clarifying intracellular events. 
The hydroquinone avarol and its quinone derivative, avarone, were isolated from the 
marine sponge Dysidea avara [8,9]. This redox couple has a large range of pharmacological 
properties including antitumor [10-12], antiinflammatory [13-15], antibacterial [16,17], antiviral 
[18,19], antioxidant [20,21], antipsoriatic [22,23] and antibiofouling [24] activities. Also, the 
compounds induced DNA damage [5,25-27] as a result of reactive oxygen radicals generation, as 
well as enzyme inhibitory [28-30] activities incurred as a consequence of modification of 
biomolecules by nucleophilic addition. 
During the search for new metabolites from marine organisms, nakijiquinones have been 
isolated. Nakijiquinones have identical sesquiterpene skeleton as avarone, including the position 
of the double bond, and additional hydroxyl and either amino acid or amine substituents at the 
quinone moiety. Kobayashi et al. have isolated a great number of these bioactive metabolites 
from the Okinawan marine sponge extracts (family Spongiidae). Nakijiquinones A and B (which 
possess glycine and valine residue attached to the quinone ring, respectively, as shown in Fig. 1) 
were the first isolated sesquiterpenoid quinones with a normal amino acid residue from natural 
origin [31]. It should be emphasized that the presence of aminoquinone compounds is not very 
rare in natural sources [32-34]. Nakijiquinone A and B show a noticeable cytotoxicity against L 
1210 murine leukemia cells and KB human epidermoid carcinoma cells, as well as antifungal 
  
activity against fungi Candida albicans and Aspergillus niger [31]. Nakijiquinones C and D (Fig. 
1), containing serine and threonine residue, respectively, were isolated from the same sponge 
family and display similar cytotoxicity [35]. Further research resulted in the isolation of two 
dimeric sesquiterpenoid quinones, nakijiquinones E and F, which did not show cytotoxicity 
against murine leukemia P388 and L1210, and KB human epidermoid carcinoma cell [36]. 
Unlike these, sesquiterpenoid quinones containing a different amine residue derived from amino 
acids, nakijiquinones G-I, showed a modest cytotoxicity against the forementioned cancer cells 
and an inhibitory activity against HER2 kinase [37]. Additionally, nakijiquinone H demonstrated 
a good antibacterial and antifungal activity [37]. Some of the nakijiquinones J-R, with amine 
residue attached to quinone ring, showed inhibitory activities against EGFR and HER2 tyrosine 
kinases [38]. Biologically active smenospongines (Fig. 1), isomeric to nakijiquinones, were 
isolated from the marine sponge Dactylospongia elegans [39] and showed a cytotoxic activity 
against a panel of tumor cell lines. 
 
 Fig. 1. Sesquiterpene quinones with an amino acid in side chain (nakijiquinones A–D; 
smenospongines B and C) 
Considering all of the above, the rationale of this work was to obtain avarone derivatives 
with amino acids, which could be considered mimics of nakijiquinones. Possible advantage of 
this approach would be to afford derivatives with better solubility in water, and a better 
  
selectivity than avarone, since it is expected that the electronic and steric effects of the amino 
acid substituent would decrease the reactivity of the quinone moiety with cellular nucleophiles. 
Different tautomeric forms of the products could have different binding properties with putative 
targets compared to avarone. Although avarone is the major constituent of the sponge Dysidea 
avara, which has been a subject of cultivation and cell culture projects, availability of large 
amounts of the compound remains a problem, so it seemed reasonable to investigate whether a 
simplification of the structure would lead to satisfactory biological activity. Therefore, a very 
simple model, tert-butylquinone was selected as target for modification, with the same amino 
acids. The model quinone is readily available.  
Thus, in this paper, the synthesis and characterization of eighteen new amino acid 
derivatives of avarone and tert-butylquinone are reported. The results of cytotoxic activity 
investigation of synthesized compounds, against five cancer cell lines and a non-cancerous cell 
line are also presented. Furthermore, effects of the derivatives on cell cycle analysis of HeLa 
cells and the caspases activity were analysed. The antibacterial activities of all the compounds 
against six strains of Gram-positive and four strains of Gram-negative bacteria were determined, 
as well as the antifungal activity against three fungal species. The biological activity of all 
derivatives was also examined by the brine shrimp test, i.e. toxicity to Artemia salina. 
Electrochemical parameters of all compounds were also determined in order to better understand 
structure–activity relationships. 
2. Results and discussion 
2.1. Chemistry 
The preparation of the derivatives is shown in Fig. 2. The synthesis started with 
commercially available tert-butylhydroquinone or avarol isolated from D. avara. The 
hydroquinones were oxidized using silver oxide to the corresponding quinones. All of the 
derivatives were obtained by slowly adding an amino acid dissolved in saturated sodium 
bicarbonate solution, to the ethanol solution of the appropriate quinone, and stirring at room 
temperature for several hours. Using all amino acids only products arising from substitution in 
position 3’ were obtained. The exception was L-proline which afforded only 4’-derivatives. In 
our previous publication [40], it was shown that good nucleophiles preferentially add in position 
  
4’ and weaker nucleophiles in position 3’. Proline is much more nucleophilic than the other 
amino acids [41].  
                      
 Fig. 2. Chemical structure of avarone and tert–butylquinone derivatives 
IR spectra, recorded as KBr discs show that the derivatives are in the form of zwitter-
ions, based on the absence of carboxylic carbonyl absorption (except for both glycine 
derivatives), and the presence of the strong carboxylate ion band at 1600–1580 cm-1. The 
presence of form III (Fig. 3) in solid state can be evidenced by a strong C–O vibration band at 
1150–1100 cm-1, and a strong broad absorption at 3600–2600 cm-1 from superimposed O–H and 
N–H stretching bands. There are two types of carbonyl stretching vibrations, a stronger band at 
ca. 1630 cm
-1
 from hydrogen bonded carbonyl group, and a weaker band at 1670 cm
-1
 from a 
non-hydrogen bonded conjugated carbonyl. The tautomeric equilibrium could be inferred from 
the severe broadening of signals in NMR spectra taken in CDCl3. However, in CD3OD the 
signals are sharp and indicate the dominant presence of quinone tautomeric forms. These forms 
are now favored since there is no need for formation of a tautomer with a hydroxylic group, 
because the protic solvent plays the role of the hydrogen bond donor. 
  
 
Fig. 3. Tautomeric forms of avarone and tert-butylquinone derivatives 
The position of the substituent on the benzoquinone ring was determined using 
1
H-NMR 
and 
13
C-NMR spectroscopy. In the proton spectra, recorded in methanol, of 3’-substituted 
derivatives signals of quinone protons are doublets with J= 2.2 Hz, while in the spectra of 4’-
substituted they are singlets. In 
13
C NMR spectra the positions of the signals are in accordance 
with the calculated values [42].  
Cyclic voltammetry was used for examination of electrochemical properties in order to 
correlate structure and bioactivity. Cyclic voltammetry measurements of avarone and amino acid 
derivatives in dimethyl sulfoxide gave two waves corresponding to reversible or quasi-reversible 
one-electron processes (Fig. 4). Such behavior is typical for redox couple quinone/semiquinone 
anion radical and semiquinone anion radical/hydroquinone dianion, respectively. Amino acid 
derivatization of avarone led to dramatic shift in potential of the first peak towards more negative 
potentials (more than 300 mV, Table 1). Consequently, the second peak is also shifted 
cathodically, but less. Generally, derivatization did not alter the reversible behavior of 
quinone/semiquinone anion radical redox system with peak separation close to ideal values. 
However, the second peak tended to be broader and/or less pronounced. As a result, semiquinone 
anion radical/hydroquinone dianion redox system resembles quasi-reversible process with peak 
separation of more than 80 mV. Destabilization of aminohydroquinone anion radical even led to 
disappearance of the second reoxidation peak in some cases. Influence of tert-butyl substituent 
followed a trend in which peak potentials were shifted negatively for around 20 mV with respect 
  
to avarone analogues. Such behavior can be easily explained by more positive inductive effect of 
tert-butyl group, and by steric congestion. This effect was more pronounced for the second peak 
with shift ranging from 30 to 90 mV. 
 
Fig. 4. Cyclic voltammogram of compounds 1, 1i, 2 and 2i 
 
Table 1. The first peak standard potential vs Fc
+
/Fc couple 
 
 
 
 
 
 
2.2. Pharmacology 
Cytotoxic activities of investigated compounds against five cancer cell lines: human 
cervix adenocarcinoma cell line (HeLa), non-small cell lung carcinoma (A549), human 
melanoma cell (Fem-X), chronic myelogenous leukemia (K562), human breast cancer (MDA-
Comp. E0 (V) Comp. E0 (V) 
1 -0.910 2 -0.933 
1a -1.187 2a -1.239 
1b -1.244 2b -1.267 
1c -1.226 2c -1.243 
1d -1.261 2d -1.252 
1e -1.265 2e -1.283 
1f -1.362 2f -1.389 
1g -1.239 2g -1.260 
1h -1.256 2h -1.255 
1i -1.256 2i -1.290 
  
MB-453) and a non-cancerous cell line, human embryonic lung fibroblast (MRC-5), were 
determined by MTT assay. The obtained results were expressed as IC50 values determined from 
cell survival diagrams and compared with a widely used anticancer drug cisplatin as positive 
control. The results are given in Table 2. Most compounds showed activity to all five cancer cell 
lines. The avarone derivatives showed a good cytotoxic activity against all the tested cancer cells 
lines, and a very weak cytotoxicity to the normal cell line. Derivatives 1c, 1d and 1e were more 
active than the parent compound against all tested cancer cell lines, with some IC50 values in the 
lower micromolar range. On the other hand, compound 1f was always less or equally active as 
avarone. Fem-X cell line was more sensitive for all avarone derivatives (exception is 1f with a 
similar value) than avarone. 
Table 2. Concentrations of compounds 1-1i and 2-2i that induced a 50 % decrease in HeLa, 
A549, Fem-X, K562, MDA-MB-453 and MRC-5 (expressed as IC50 (μM)). All compounds were 
incubated with cells for 72 h. 
 
Comp. HeLa A549 Fem-X K562 MDA-MB-453 MRC-5 
1 18.12 ± 0.68 30.03 ± 2.88 40.33 ± 2.88 17.08 ± 0.35 16.71 ± 1.74 >200 
1a 19.87 ± 1.15 46.71 ± 2.53 17.84 ± 1.34 15.63 ± 1.08 5.84 ± 0.92 183.29 ± 1.15 
1b 11.66 ± 1.74 54.29 ± 1.01 10.29 ± 1.15 15.75 ± 0.19 14.65 ± 1.62 157.38 ± 2.14 
1c 8.87 ± 1.08 26.91 ± 0.25 20.24 ± 2.89 15.47 ± 1.86 3.31 ± 0.71 80.76 ± 1.54 
1d 10.92 ± 1.33 23.77 ± 1.21 11.43 ± 0.61 7.78 ± 0.20 8.01 ± 0.57 85.42 ± 1.88 
1e 7.72 ± 0.89 19.72 ± 2.83 10.87 ± 0.16 11.17 ± 2.83 10.93 ± 0.51 73.39 ± 1.86 
1f 36.23 ± 0.09 49.21 ± 0.75 39.63 ± 1.13 35.44 ± 1.76 60.63 ± 0.06 96.02 ± 2.24 
1g 13.91 ± 1.98 47.31 ± 2.86 19.43 ± 1.03 13.58 ± 1.72 25.58 ± 1.20 >200 
1h 14.64 ± 1.16 40.08 ± 3.43 17.26 ± 1.59 20.46 ± 0.87 16.55 ± 0.93 >200 
1i 16.24 ± 2.29 39.56 ± 2.21 14.82 ± 2.22 16.12 ± 0.29 22.94 ± 1.82 157.39 ± 2.19 
2 44.08 ± 2.11 47.02 ± 1.27 41.64 ± 2.55 15.54 ± 1.48 56.83 ± 2.07 >200 
2a 131.67 ± 2.76 >200 34.33 ± 0.84 85.02 ± 1.61 171.26 ± 2.35 >200 
2b 89.12 ± 4.09 >200 20.11 ± 1.53 77.63 ± 2.38 112.24 ± 1.73 >200 
2c 47.11 ± 3.22 171.21 ± 3.27 28.42 ± 0.95 66.96 ± 2.42 94.09 ± 1.23 >200 
2d 96.55 ± 1.08 154.47 ± 0.75 24.55 ± 0.34 57.84 ± 1.57 133.25 ± 0.55 >200 
2e 57.22 ± 0.34 97.93 ± 0.42 39.37 ± 2.32 76.54 ± 1.91 84.89 ± 0.43 >200 
2f 44.94 ± 0.69 186.03 ± 2.47 87.30 ± 1.31 49.24 ± 2.69 67.17 ± 1.04 >200 
2g 77.41 ± 0.24 >200 34.82 ± 1.73 88.51 ± 1.33 150.95 ± 2.57 >200 
2h 66.31 ± 1.52 164.17 ± 3.51 67.29 ± 1.11 82.26 ± 2.36 68.01 ± 1.18 >200 
2i 106.31 ± 1.77 198.04 ± 1.21 34.71 ± 1.12 25.04 ± 3.23 119.86 ± 1.27 >200 
Cisplatin 2.1 ± 0.20 11.92 ± 2.19 4.71 ± 0.20 6.89 ± 0.21 3.48 ± 0.22 14.21 ± 1.54 
  
 
Compound 1c showed the highest activity against the human breast cancer cell line, 
MDA-MB-453, with IC50 value similar to that for cisplatin. It should be pointed out that 1c 
unlike cisplatin showed a significantly lower cytotoxicity against MRC-5 cell line. The best 
selectivity was observed for 1a against the MDA-MB-453 cell line. Compound 1a was almost 
thirteen times less active against the non-tumor cell line than the positive control.  
Only some structure-activity relations could be established. The activity was generally 
enhanced by introducing both small (including β-alanine) and voluminous amino acids with 
aliphatic hydrocarbon side chain.  
Aromatic side chain did not improve the activity and proline residue decreased both the 
activity and the selectivity. Glycine and β-alanine derivatives were selective for the breast cancer 
cell line, while alanine, valine, leucine and isoleucine derivatives showed a high activity, but 
without a pronounced specificity among the tumor cell lines, although they displayed an 
excellent selectivity for tumor cell lines compared to the normal MRC-5 cell line. 
Electrochemical results have shown that introduction of amino acid substituents did not 
significantly change redox properties, i.e. the quinones still underwent two one–electron 
reduction processes, with semiquinone intermediates. The reduction potentials for all derivatives 
are more negative than for the parent compound, indicating a more favourable reoxidation of 
semiquinone radicals with oxygen, generating reactive superoxide radical which can 
subsequently produce other reactive oxygen species. However, the differences in activity cannot 
be ascribed to redox properties, since the redox potentials do not differ within this series of 
compounds. Even the lower activity of the proline derivative is probably not a consequence of its 
more negative redox potential, since the whole set of compounds have a lower redox potential 
and mostly a higher cytotoxicity than the parent compound. 
The derivatives of the avarone mimic, tert-butylquinone, although non-cytotoxic to 
normal cells showed a much lower activity than the corresponding avarone derivatives. 
Structure–activity relationships could not be established within this series of compounds. 
  
The results can be compared with those of some 4’-amino acid avarone derivatives. 4’-
Alanino, 4’-phenylalanino and 4’-leucino avarone derivatives showed a strong activity to L1210 
mouse leukemia cells (IC50 ca.10 μM), however without selectivity in comparison to normal cells 
[43]. Cytotoxic activity of 4’-leucinoavarone was recently studied in more details [44,45]. The 
panel of seven tumor cell lines and one normal cell line was used, and the IC50 values from 4 to 
17 μM were obtained for tumor cells and >100 μM for normal cell line MRC-5. The results for 
three cell lines can be compared to those of the regioisomeric 3’-leucino derivative presented in 
this paper. The activities were similar – 4’-derivative was slightly more active to A549 cells, and 
3’-derivative to HeLa cells. In another recent publication cytotoxicity of amino acid derivatives 
of 1,4–naphthoquinone was assayed against a panel of tumor cells, and normal PBMC 
(peripheral blood mononuclear cells) [46]. For this type of compounds, glycine, alanine and 
phenylalanine derivatives showed a better activity than β-alanine and proline ones. The best 
selectivity with respect to normal cells was attained with phenylalanine derivatives. 
Given that compounds 1c-e and 1g showed the highest cytotoxicity towards HeLa cells, 
these compounds were selected for examination of the mechanism of action by cytofluorimetric 
analysis, using propidium iodide to label DNA. Based on the results of MTT test, the IC50 and 
2IC50 concentrations of compounds were used to verify cell cycle arrest. Figs 5 and 6 show the 
cell-cycle distribution of HeLa cells incubated in the absence or presence of compounds for 24 
hours, the approximate doubling time of this cell line. The results indicate an alteration in the 
percentage of cells in each stage of the cell cycle: sub-G1, G1, S and G2/M, as compared to the 
control. For 1d and 1e at applied concentrations a significant increase in the number of cells in 
the sub-G1 phase and a corresponding decrease in the G1 phase were observed as compared to 
the control cells. In contrast, compounds 1c and 1g caused G2/M arrest after 24 h of treatment. 
For compound 1d sub-G1 accumulation was accompanied by a slightly heightened G2/M cell 
cycle blockade. In addition, as shown in Figs 5 and 6, the sub-G1 and G2/M arrest was detected 
in a concentration-dependent manner. The present study suggests that the cell cycle arrest and 
induction of apoptosis might be one possible mechanism of action of these compounds in human 
cancer cells. The greatest effect, both in cytotoxicity and in cell cycle perturbation and induction 
of apoptosis was achieved with avarone derivatives with branched amino acid chains.  
  
 
Fig. 5. Cell cycle distribution after 24 h continuous action of investigated compounds. 
Concentration corresponded to IC50. 
  
Fig. 6. Cell cycle distribution after 24 h continuous action of investigated compounds. 
Concentration corresponded to 2IC50. 
To examine the mechanism of apoptosis induced by the investigated compounds in HeLa 
cells, caspase activities for two most active compounds 1c and 1e were measured using specific 
caspase inhibitors. The activity of caspases 3, 8 and 9, was evaluated after 24 h of incubation 
with 1c or 1e (Fig. 7).  
  
 
Fig. 7. Influence of compounds 1c (A) and 1e (B) alone or in combination with inhibitors of 
caspase-3 (Z-DEVD-FMK), caspase-8 (Z-IETD-FMK) or caspase-9 (Z-LEHD-FMK) on the 
fraction of HeLa cells in sub-G1 phase. 
The results show that the apoptosis induced by compounds 1c and 1e was mediated by 
stimulating caspase-3, -8 and -9 activities. It is evident that specific inhibitors significantly 
suppressed the caspase activities and increased the cell viability. In addition, the inhibitor of 
caspase-3 shows a much weaker influence on the activity of the investigated compounds, 
suggesting the induction of apoptotic cell death mainly via mitochondrial pathway through 
activation of caspases 8 and 9 in HeLa cells. Generally, the activation of caspases 3, 8 and 9 
might be involved in apoptosis induced by compounds in HeLa cells. 
Antibacterial activities of all the compounds against six strains Gram-positive and four 
Gram-negative bacteria were determined as MIC values (µM) (Table 3). Generally, avarone 
compounds demonstrated significantly stronger activities than tert-butylquinone derivatives. All 
avarone derivatives had MIC values below or similar to 100 µM against Staphylococcus aureus, 
Micrococcus luteus and Escherichia coli. The weakest activity was shown against the Gram-
positive bacteria Kocuria rhizophila. Antibacterial effect of the compound 1e to S. aureus and E. 
coli was the most pronounced. Its MIC values indicate a remarkably stronger antibacterial 
activity than amikacin, antibiotic used as positive control. Bacterial strain M. luteus was also 
more sensitive to 1e than amikacin. The results for compounds 1h and 1i showed a good activity 
against Bacillus subtilis and Pseudomonas aeruginosa, better than amikacin. The compound 1h 
showed an excellent activity against S. aureus and M. luteus, and again higher than that of 
amikacin. In comparison with avarone, all derivatives showed a stronger activity against M. 
  
luteus and E. coli. The structure–activity relationships are different from those for cytotoxicity to 
tumor cells, since the best activity was shown by derivatives with voluminous and aromatic side 
chains, while small amino acid moieties decreased the activity in comparison to avarone.  
Table 3. Antibacterial activity of avarone and tert-butylquinone derivatives (MIC values in μM) 
 
Antifungal activity was evaluated against three fungal species (Table 4). All of the 
avarone derivatives were significantly more active against Candida albicans and Saccharomyces 
cerevisiae than the positive control nystatin. Also, almost all of the derivatives showed 
substantial activity against Aspergillus brasiliensis, better than nystatin. The compounds 1d and 
1g showed more than a thousand times stronger activity against C. albicans in comparison to 
nystatin. Similar effects were produced with 1b and 1e. The species S. cerevisiae was extremely 
sensitive to the compound 1i. tert-Butylquinone derivatives were also more active against C. 
albicans and S. cerevisiae than the positive control nystatin. However, their activity was again 
Comp. S. aureus K. rhizophila B. subtilis M. luteus M. flavus C. sporogenes E. coli P. hauseri S.enterica P. aeruginosa 
1 40.06 20.03 80.13 2000.38 20.03 20.03 440.96 27.56 55.12 13.78 
1a 101.04 810.88 406.74 101.04 406.74 406.74 101.04 810.88 406.74 406.74 
1b 49.10 1566.42 195.49 97.74 195.49 195.04 49.10 393.48 195.49 195.49 
1c 24.53 392.97 392.97 48.81 783.44 392.97 48.81 392.97 783.44 783.44 
1d 22.95 1463.70 91.33 22.95 91.33 91.33 22.95 182.67 182.67 91.33 
1e 5.55 708.79 88.32 11.10 88.32 44.16 5.55 44.16 88.32 88.32 
1f 91.55 734.74 183.10 91.55 183.10 368.54 91.55 183.10 183.10 183.10 
1g 42.39 1358.70 169.57 42.39 169.57 169.57 42.39 341.30 169.57 169.57 
1h 10.32 330.53 20.63 10.32 82.11 82.11 10.32 82.11 20.63 20.63 
1i 19.07 305.45 37.94 19.07 37.94 37.94 19.07 37.94 19.07 37.94 
2 237.51 475.03 237.51 237.51 475.03 475.03 237.51 475.03 475.03 475.03 
2a 662.45 2637.13 1320.68 662.45 2637.13 2637.13 662.45 2637.13 2637.13 662.45 
2b 1247.01 4980.08 2490.04 1247.02 2490.04 2490.04 1247.01 4980.08 2490.04 2490.04 
2c 624.80 2487.27 2487.27 1245.62 2487.27 1245.62 1245.62 2487.27 2487.27 2487.27 
2d 1121.86 4480.29 2240.14 1121.86 2240.14 2240.14 1121.86 4480.28 4480.28 2240.14 
2e 265.88 2130.49 2130.49 265.88 2130.49 2130.49 265.88 2130.49 2130.49 4260.98 
2f 566.79 2256.32 1129.96 566.79 2256.32 2256.32 566.79 2256.32 2256.32 2256.32 
2g 1006.43 2009.64 2009.65 504.82 2009.64 2009.65 1006.43 2009.65 2009.65 2009.64 
2h 480.12 1911.32 1911.32 480.12 1911.32 1911.32 480.12 1911.32 1911.32 1911.32 
2i 855.19 1707.65 1707.65 1707.65 1707.65 1707.65 1707.65 1707.65 1707.65 1707.65 
Amikacin 18.78 3.42 71.72 13.65 3.42 25.61 8.54 11.95 13.66 85.38 
  
much weaker than that of avarone derivatives. Besides the effect of the alkyl group bound to the 
quinone nucleus, no structure–activity correlation could be established. 
Table 4. Antifungal activity of avarone and tert-butylquinone derivatives (MIC values in μM) 
 
 
 
 
 
 
 
 
 
 
 
a Not active. 
 
The biological activity of all compounds was examined by the brine shrimp test, i.e. 
toxicity to Artemia salina (Table 5). The results of this test are reported to show a good 
qualitative correlation with cancer cell-line cytotoxicity. The avarone derivatives showed a good 
correlation with antileukemic activity, the most effective compound being 1d, while 1f 
demonstrated the lowest activity. tert-Butylquinone compounds, except the parent quinone, were 
less active in this test, too. 
 
Compound C. albicans S.cerevisiae A. brasiliensis 
1 n.a
a n.aa n.aa 
1a 12.60 100.26 403.60 
1b 6.13 195.00 1562.50 
1c 195.00 12.25 782.50 
1d < 2.88 367.68 164.13 
1e < 5.54 176.47 1414.03 
1f 23.01 45.77 734.74 
1g < 2.67 87.78 341.30 
1h 164.21 10.32 1315.79 
1i 305.45 < 2.39 1215.95 
2 121.80 237.51 121.80 
2a 662.45 662.45 2637.13 
2b 625.50 625.50 1240.01 
2c 625.50 310.76 2490.04 
2d 562.72 562.72 2240.14 
2e 535.84 133.11 1068.26 
2f 566.79 566.79 2256.32 
2g 504.82 504.82 2009.65 
2h 480.12 119.27 957.19 
2i 213.11 213.11 1407.65 
Nystatin 2700.00 1350.00 1350.00 
  
Table 5. Brine shrimp test results of avarone and tert-butylquinone derivatives 
 
 
 
 
 
 
 
 
 
 
 
3. Conclusion 
In summary, nine amino acid derivatives of marine quinone avarone (1) and the same 
number of derivatives of model system tert-butylquinone (2) were obtained. Cytotoxic activities 
of synthesized compounds towards five cancer cell lines: HeLa, A549, Fem-X, K562, MDA-
MB-453 and a non-cancerous cell line MRC-5 were determined by MTT assay. Most tested 
avarone derivatives had a good antitumor activity with IC50 values lower than for parent 
compound. The strongest cytotoxic activity, similar to widely used drug cisplatin, was displayed 
by derivative 1c (IC50 3.31 µM against MDA-MB-453). Towards HeLa cells, compounds 1b-e 
and 1g showed the highest cytotoxicity. These derivatives were chosen for investigation of cell 
cycle by cytofluorimetric analysis. The tested compounds showed different effects on cell cycle. 
Compounds 1d and 1e led to an increase in a number of cells in the sub-G1 phase while 
derivatives 1c and 1g caused G2/M arrest. The obtained results show that apoptosis might be the 
most likely mechanism of action of investigated compounds. Further research of the mechanism 
Compound LC50 (ppm) 
1 170.00 
1a 487.10 
1b 129.40 
1c 84.30 
1d 50.50 
1e 117.00 
1f 706.60 
1g 147.70 
1h 96.70 
1i 227.40 
2 27.40 
2a 197.40 
2b 393.80 
2c 833.20 
2d 574.90 
2e 104.80 
2f 883.40 
2g 360.20 
2h 196.80 
2i 334.10 
  
of apoptosis was evaluated using specific caspase inhibitors. The results suggested that 
derivatives 1c and 1e activated caspases 8 and 9, and that cell death occurred via mitochondrial 
pathway. 
The synthesized compounds were tested toward a panel of Gram positive and Gram 
negative bacteria, as well as several fungi strains. Some of derivatives showed a significant 
antimicrobial activity, especially avarone agents against C. albicans and S. cerevisiae, while 
parent compound was not active.  
4. Experimental protocols 
4. 1. Chemistry   
Melting points (°C, uncorrected) were determined on a Boetius PHMK apparatus (VEB 
Analytic, Dresden, Germany). 
1
H and 
13
C NMR spectra were recorded at 200 MHz and 50 MHz, 
respectively on Varian YH 200 instrument, in deuterated methanol using tetramethylsilane as an 
internal standard. Numeration scheme is given in the Supplementary material. High resolution 
mass spectra were taken on Mass Spectrometer 6210 Time of Fligth LC-MS system, Agilent 
Technologies. UV/Vis spectra were recorded on a Cintra 40 UV-Visible spectrometer. 
Polarimetric measurements were performed on a Rudolph research analytical polarimeter, 
Autopol IV, in methanol. IR spectra were recorded on Thermo Scientific Nicolet 6700 FT-IR 
(Smart orbit).  
Cyclic voltammetry experiments were performed at room temperature under nitrogen 
atmosphere in a three-electrode cell at 25 ºC and using a CHI760B workstation (CH Instruments, 
Austin TX, USA). The working electrode was glassy carbon disk (3 mm diameter). The counter 
electrode was a platinum wire, and a silver wire immersed in electrolyte solution containing 0.01 
M silver ions was used as the reference electrode. The quinone derivatives were used as 2 mM 
solution in dimethyl sulfoxide, with 0.1 M tetraethylammonium perchlorate as an electrolyte.  
Avarol was isolated from the sponge Dysidea avara collected in the Bay of Kotor, 
Montenegro, and oxidized with silver oxide in order to obtain avarone as described above. 
All reagents used were commercial products purchased from Merck and Sigma-Aldrich. 
Column chromatography was carried out on silica gel (0.063-0.200 mm, Merck). Analytical thin-
  
layer chromatography (TLC) was performed on precoated aluminum-backed plates (silica gel 60 
F254, Fluka). 
4.1.1. Synthesis of derivatives, general procedure 
4.1.1.1. N-[3-[[(1R,2S,4aS,8aS)-1,2,3,4,4a,7,8,8a-octahydro-1,2,4a,5-tetramethyl-1-
naphthalenyl)methyl]-2.5-dioxo-1,4-cyclohexadien-1-yl]glycine (1a) 
 Glycine (240 mg) was dissolved in 100 ml of saturated solution of NaHCO3, and a few 
drops of aqueous solution of NaOH until pH 10 was added. Solution was added in portions to the 
100 ml of ethanol solution of avarone (200 mg) and the color changed from yellow to red. The 
reaction mixture was stirred for 4.5 h at room temperature. After ethanol was eliminated, the 
remaining aqueous solution was extracted with ethyl acetate and the solution was dried over 
anhydrous Na2SO4. After the evaporation of ethyl acetate, the product was purified by 
preparative TLC (silica gel GF254, 1 mm) using chloroform/methanol (9:1) as the eluent, and re-
chromatographed with the same eluent. Compound 1a was obtained after recrystallization in 
dichlormethane overnight as red crystals (107 mg; yield 43 %). Mp: 86–88 ºC; [α]D
20 
= –16 (c 
0.250, CH3OH); 
1
H NMR (200 MHz, CD3OD): δ 6.33 (d, J= 1.6 Hz, 1H, C6’-H), 5.32 (d, J= 1.6 
Hz, 1H, C4’-H), 5.09 (brs, 1H, C3-H), 3.62 (s, 2H, C7’-H), 2.57 (d, J= 13.4 Hz, 1H, C11- Ha), 
2.45 (d, J= 13.4 Hz, 1H, C11- Hb), 1.49 (s, 3H, C12-H), 0.98 (s, 3H, C13-H), 0.93 (d, J=6.2 Hz, 
3H, C14-H), 0.82 (s, 3H, C15-H); 
13
C NMR (50 MHz, CD3OD): δ 187.1 (C5’), 184.5 (C2’), 
174.6 (C8’), 148.6 (C3’), 144.9 (C4), 143.8 (C1’), 140.8 (C6’), 121.6 (C3), 97.6 (C4’), signal 
overlapped with solvent signal (C10), 47.0 (C7’), 43.0 (C9), 39.4 (C5), 38.0 (C8), 37.3 (C6), 
36.1 (C11), 28.6 (C7), 27.3 (C2), 20.5 (C1), 20.3 (C13), 18.4 (C14), 18.1 (C12), 17.2 (C15); IR 
(KBr, cm
-1
): 3456.7, 3330.3, 2959.4, 2930.5, 2860.9, 1725.4, 1673.9, 1636.4, 1593.8, 1457.8, 
1382.0, 1352.7, 1262.6, 1125.8, 1073.6, 739.1; CIMS (MeOH): 386.23150 [M+1]
+
; UV/Vis 
(MeOH): λmax (log ε) 286 (4.73), 482 (4.20).  
4.1.1.2. N-[3-[[(1R,2S,4aS,8aS)-1,2,3,4,4a,7,8,8a-octahydro-1,2,4a,5-tetramethyl-1-
naphthalenyl)methyl]-2,5-dioxo-1,4-cyclohexadien-1-yl]-(S)alanine (1b) 
Obtained by the same procedure as 1a, using 200 mg avarone and 179 mg L-alanine, but 
without addition of aqueous solution of NaOH. The reaction time was shortened to 3.5 h and 
reaction mixture was extracted with chloroform. The crude product was chromatographed on a 
  
silica gel 60 column, using chloroform/methanol (8:2) as the eluent, and rechromatographed by 
preparative TLC (silica gel GF254, 1 mm, eluent chloroform/methanol (8:2)), affording 1b as red 
crystals (65 mg; yield 25 %). Mp: 168–171 ºC (dec.); [α]D
20 
= 56 (c 0.125, CH3OH); 
1
H NMR 
(200 MHz, CD3OD): δ 6.24 (d, J= 2.4 Hz, 1H, C6’-H), 5.27 (d, J=2.4 Hz, 1H, C4’-H), 5.02 (brs, 
1H, C3-H), 3.71 (q, J=6.8 Hz, 1H, C7’-H), 2.48 (d, J= 6.2Hz, 1H, C11- Ha), 2.41 (d, J= 6.2 Hz, 
1H, C11- Hb), 1.42 (s, 3H, C12-H), 1.33 (d, J= 6.8 Hz, 3H, C9’-H), 0.92 (s, 3H, C13-H), 0.86 
(d, J= 6.0 Hz, 3H, C14-H), 0.76 (s, 3H, C15-H); 
13
C NMR (50 MHz, CD3OD): δ 187.2 (C5’), 
184.7 (C2’), 178.7 (C8’), 148.1 (C3’), 145.2 (C4), 144.0 (C1’), 140.7 (C6’), 121.6 (C3), 97.7 
(C4’), 54.1 (C7’), signal overlapped with solvent signal (C10), 43.1 (C9), 39.6 (C5), 38.0 (C8), 
37.4 (C6), 36.1 (C11), 28.6 (C7), 27.4 (C2), 20.5 (C1), 20.4 (C13), 18.3 (C14), 18.1 (C12), 17.3 
(C9’), 17.2 (C15); IR (KBr, cm-1): 3363.9, 2960.8, 2931.4, 2855.5, 1670.7, 1633.0, 1583.0, 
1498.8, 1455.0, 1416.4, 1358.7, 1335.0; CIMS (MeOH): 400.24715 [M+1]
+
; UV/Vis (MeOH): 
λmax (log ε) 290 (4.65), 492 (4.26).  
4.1.1.3. N-[3-[[(1R,2S,4aS,8aS)-1,2,3,4,4a,7,8,8a-octahydro-1,2,4a,5-tetramethyl-1-
naphthalenyl)methyl]-2,5-dioxo-1,4-cyclohexadien-1-yl]β-alanine (1c) 
Obtained by the same procedure as 1a, using 100 mg avarone and 143 mg β-alanine. The 
reaction time was shortened to 3 h. Rechromatography was not necessary. 1c: red crystals; 43 mg 
(yield 34 %). Mp: 120–122 ºC; [α]D
20 
= 64 (c 0.250, CH3OH); 
1
H NMR (200 MHz, CD3OD): δ 
6.32 (d, J= 2.8 Hz, 1H, C6’-H), 5.46 (d, J= 2.8Hz, 1H, C4’-H), 5.11 (brs, 1H, C3-H), 3.34 (t, J= 
5.2 Hz, 2H, C7’-H), 2.60 (d, J= 5 Hz, 1H, C11- Ha), 2.53 (d, J= 5 Hz, 1H, C11- Hb), 2.45 (t, J= 
6.6 Hz, 2H, C8’-H), 1.51 (s, 3H, C12-H), 1.00 (s, 3H, C13-H), 0.93 (d, J=6.2 Hz, 3H, C14-H), 
0.83 (s, 3H, C15-H); 
13
C NMR (50 MHz, CD3OD): δ 187.1 (C5’), 184.7 (C2’), 179.5 (C9’), 
149.4 (C3’), 145.0 (C4), 143.9 (C1’), 140.7 (C6’), 121.6 (C3), 97.0 (C4’), signal overlapped 
with solvent signal (C10), 43.0 (C9), 40.8 (C7’), 39.5 (C5), 38.1 (C8), 37.4 (C6), 36.7 (C8’), 
36.1 (C11), 28.6 (C7), 27.4 (C2), 20.5 (C1), 20.3 (C13), 18.3 (C14), 18.1 (C12), 17.2 (C15); IR 
(KBr, cm
-1
): 3386.4, 2960.3, 2858.0, 1671.2, 1633.3, 1583.1, 1513.4, 1451.4, 1382.3, 1254.3, 
1143.6, 1030.4; CIMS (MeOH): 400.24846 [M+1]
+; UV/Vis (MeOH): λmax (log ε) 290 (4.75), 
490 (4.33).  
4.1.1.4. N-[3-[[(1R,2S,4aS,8aS)-1,2,3,4,4a,7,8,8a-octahydro-1,2,4a,5-tetramethyl-
1-naphthalenyl)methyl]-2,5-dioxo-1,4-cyclohexadien-1-yl]-(R)valine (1d) 
  
Obtained by the same procedure as 1a, using 100 mg avarone and 113 mg D-valine. The 
reaction time was shortened to 3 h and after evaporation of ethyl acetate the product was purified 
by preparative TLC (silica gel GF254, 1 mm, eluent toluene/ethyl acetate (9:1)). 1d: red crystals; 
55 mg (yield 40 %). Mp: 197–200 ºC; [α]D
20 
= –36 (c 0.250, CH3OH); 
1
H NMR (200 MHz, 
CD3OD): δ 6.33 (d, J= 2.8 Hz, 1H, C6’-H), 5.42 (d, J= 2.8 Hz, 1H, C4’-H), 5.11 (brs, 1H, C3-
H), 3.60 (d, J= 4.6 Hz, 1H, C7’-H), 2.59 (d, J= 14 Hz, 1H, C11- Ha), 2.48 (d, J= 14 Hz, 1H, 
C11- Hb), 2.19 (m, 1H, C9’-H), 1.51 (s, 3H, C12-H), 1.07 (d, J= 1.6 Hz, 3H, C10’-H), 1.01 (s, 
3H, C13-H), 0.99 (d, J= 1.6 Hz, 3H, C11’-H), 0.96 (d, J=  2.2 Hz, 3H, C14-H), 0.85 (s, 3H, 
C15-H); 
13
C NMR (50 MHz, CD3OD): δ 187.3 (C5’), 184.7 (C2’), 177.6 (C8’), 148.7 (C3’), 
145.0 (C4), 143.9 (C1’), 140.7 (C6’), 121.7 (C3), 97.7 (C4’), 64.7 (C7’), signal overlapped with 
solvent signal (C10), 43.1 (C9), 39.6 (C5), 38.3 (C8), 37.4 (C6), 36.3 (C11), 32.4 (C9’), 28.6 
(C7), 27.4 (C2), 20.5 (C1, C11’), 19.8 (C13), 19.2 (C14), 18.3 (C10’), 18.0 (C12), 17.2 (C15); 
IR (KBr, cm
-1
): 3356.7, 2961.7, 2931.1, 2875.4, 1670.7, 1632.8, 1580.2, 1507.5, 1417.7, 1384.8, 
1344.5, 1288.5, 1124.4, 1092.5, 644.2, 612.2; CIMS (MeOH): 428.27917 [M+1]
+
; UV/Vis 
(MeOH): λmax (log ε) 286 (4.68), 498 (4.34). 
4.1.1.5. N-[3-[[(1R,2S,4aS,8aS)-1,2,3,4,4a,7,8,8a-octahydro-1,2,4a,5-tetramethyl-1-
naphthalenyl)methyl]-2,5-dioxo-1,4-cyclohexadien-1-yl]-(S)leucine (1e)      
Obtained by the same procedure as 1a, but the reaction time was prolonged to 5 h and the 
crude product was first purified by preparative TLC (silica gel GF254, 1 mm, eluent toluene/ethyl 
acetate (9:1)). Starting from 100 mg avarone and 126 mg L-leucine, 1e was obtained as red 
crystals (42 mg; yield 30 %). Mp: 148–150 ºC; [α]D
20 
= –24 (c 0.250, CH3OH); 
1
H NMR (200 
MHz, CD3OD): δ 6.32 (d, J= 2.8 Hz, 1H, C6’-H), 5.39 (d, J=2.8 Hz, 1H, C4’-H), 5.103 (brs, 1H, 
C3-H), 3.77 (t, J= 5.6 Hz, 1H, C7’-H), 2.52 (d, J= 14.0 Hz, 1H, C11- Ha), 2.46 (d, J= 14 Hz, 1H, 
C11- Hb), 1.71 (m, 3H, C9’, C10’), 1.51 (s, 3H, C12-H), 1.01 (s, 3H, C13-H), 0.89 (d, J= 6.2 
Hz, 3H, C14-H), 0.96 (s, 3H, C11’), 0.93 (s, 3H, C12’), 0.84 (s, 3H, C15-H); 13C NMR (50 
MHz, CD3OD): δ 187.2 (C5’), 184.7 (C2’), 178.2 (C8’), 148.6 (C3’), 145.2 (C4), 144.0 (C1’), 
140.6 (C6’), 121.5 (C3), 97.5 (C4’), 58.0 (C7’), signal overlapped with solvent signal (C10), 
43.1 (C9), 42.0 (C9’), 39.6 (C5), 37.8 (C8), 37.4 (C6), 36.0 (C11), 28.6 (C7), 27.4 (C2), 26.4 
(C10’), 23.5 (C11’), 22.8 (C12’), 20.5 (C1), 20.3 (C13), 18.3 (C14), 18.1 (C12), 17.2 (C15); IR 
(KBr, cm
-1
): 3368.4, 1670.0, 1632.7, 1581.0, 1512.1, 1449.6, 1384.4, 1343.1, 1257.4, 1121.1, 
  
1029.4, 737.1, 702.6, 613.5; CIMS (MeOH): 442.29476 [M+1]
+; UV/Vis (MeOH): λmax (log ε) 
286 (4.62), 494 (4.24).  
4.1.1.6. N-[4-[[(1R,2S,4aS,8aS)-1,2,3,4,4a,7,8,8a-octahydro-1,2,4a,5-tetramethyl-1-
naphthalenyl)methyl]-2,5-dioxo-1,4-cyclohexadien-1-yl]-(S)proline (1f)    
Obtained by the same procedure as 1a, using 110 mg avarone and 122 mg L-proline, but 
the color changed from yellow to purple. The reaction time was shortened to 1.5 h and the 
product was purified by preparative TLC (silica gel GF254, eluent toluene/ethyl acetate (9:1)), 
then rechromatographed with the chloroform/methanol (8:2) as the eluent. Compound 1f was 
obtained as red-purple crystals (28 mg; yield 19 %). Mp: 193–195 ºC (dec.); [α]D
20 
= –120 (c 
0.125, CH3OH); 
1
H NMR (200 MHz, CD3OD): δ 6.13 (brs, 1H, C6’-H), 5.37 (brs, 1H, C3’-H), 
5.00 (bs, 1H, C3-H),  3.57-3.42 (m, 3H, C7’-H, C10’-H), 2.51 (d, J= 13.0 Hz, 1H, C11- Ha), 
2.38 (d, J= 13.0 Hz, 1H, C11- Hb), 2.19-2.05 (m, 2H, C9’-H), 2.05-1.85 (broad signal, 2H, C8’-
H), 1.41 (s, 3H, C12-H), 0.91 (s, 3H, C13-H), 0.85 (d, J= 6.2 Hz, 3H, C14-H), 0.75 (s, 3H, C15-
H); 
13
C NMR (50 MHz, CD3OD): δ 186.3 (C2’), 185.7 (C5’), 180.0 (C11’), 150.1 (C1’), 148.9 
(C4’), 144.9 (C4), 134.5 (C6’), 121.7 (C3), 102.5 (C3’), 66.9 (C10’), signal overlapped with 
solvent signal (C10), 43.7 (C9), 39.5 (C5), 38.2 (C8), 37.4 (C6), 36.1 (C11), 33.0 (C9’), 30.7 
(C8’), 28.7 (C7), 27.4 (C2), 20.5 (C1), 20.4 (C13), 18.3 (C14), 18.2 (C12), 17.3 (C15); IR 
(KBr, cm
-1
): 3377.8, 2959.8, 2925.5, 2876.4, 1658.7, 1629.5, 1590.2, 1563.9, 1452.0, 1420.8, 
1144.6; CIMS (MeOH): 426.26373 [M+1]
+; UV/Vis (MeOH): λmax (log ε) 296 (4.67), 512 
(4.34).  
4.1.1.7. N-[3-[[(1R,2S,4aS,8aS)-1,2,3,4,4a,7,8,8a-octahydro-1,2,4a,5-tetramethyl-1-
naphthalenyl)methyl]-2,5-dioxo-1,4-cyclohexadien-1-yl]-(S)methionine (1g)  
Obtained by the same procedure as 1a, using 200 mg avarone and 239 mg L-methionine. 
The reaction time was prolonged to 5 h. The product was purified using toluene/ethyl acetate 
(9:1) as the eluent and then rechromatographed with the eluent chloroform/methanol (8:2). 1g: 
red crystals; 45 mg (yield 15 %). Mp: 164–168 ºC; [α]D
20 
= –12 (c 0.250, CH3OH); 
1
H NMR 
(200 MHz, CD3OD): δ 6.33 (d, J= 2.2 Hz, 1H, C6’-H), 5.45  (d, J= 2.2 Hz, 1H, C3’-H), 5.10 
(brs, 1H, C3-H), 3.89 (dd, J= 5.6 Hz, J= 9.0 Hz, 1H, C7’-H), 2.66-2.37 (m, 4H, C11- Ha, C11- 
Hb, C10’-H), 2.17-2.10 (m, 2H, C9’-H), 2.04 (s, 3H, C11’-H), 1.50 (s, 3H, C12-H), 1.00 (s, 3H, 
  
C13-H), 0.94 (d, J= 6.2 Hz, 3H, C14-H), 0.84 (s, 3H, C15-H); 
13
C NMR (50 MHz, CD3OD): δ 
187.2 (C5’), 184.6 (C2’), 176.9 (C8’), 148.3 (C3’), 145.1 (C4), 144.1 (C1’), 140.6 (C6’), 121.5 
(C3), 97.7 (C4’), 57.9 (C7’), signal overlapped with solvent signal (C10), 43.1 (C9), 39.5 (C5), 
37.8 (C8), 37.4 (C6), 35.9 (C11), 32.1 (C9’), 31.1 (C10’), 28.5 (C7), 27.4 (C2), 20.5 (C1), 20.3 
(C13), 18.3 (C14), 18.1 (C12), 17.1 (C15), 15.4 (C11’); IR (KBr, cm-1): 3350.0, 2959.2, 2931.1, 
2857.9, 1669.7, 1632.1, 1584.4, 1489.0, 1442.6, 1384.6, 1339.1, 1284.1, 1144.8, 1029.6, 628.8; 
CIMS (MeOH): 460.25091 [M+1]
+; UV/Vis (MeOH): λmax (log ε) 290 (4.59), 490 (4.20).  
4.1.1.8. N-[3-[[(1R,2S,4aS,8aS)-1,2,3,4,4a,7,8,8a-octahydro-1,2,4a,5-tetramethyl-1-
naphthalenyl)methyl]-2,5-dioxo-1,4-cyclohexadien-1-yl]-(S)phenylalanine (1h)  
Obtained by the same procedure as 1a, using 190 mg avarone and 100 mg L- 
phenylalanine and the reaction time was prolonged to 5 h. After the evaporation of ethyl acetate, 
the product was purified by preparative TLC (silica gel GF254, 1 mm, eluent toluene/ethyl acetate 
(9:1), affording 1h as red crystals (28 mg; yield 10 %). Mp: 155–158 ºC; [α]D
20 
= 60 (c 0.250, 
CH3OH); 
1
H NMR (200 MHz, CD3OD): δ 7.20-7.08 (broad signal, 5H, Ph-H), 6.26 (d, J= 2.2 
Hz, 1H, C6’-H), 5.21 (d, J= 2.2 Hz, 1H, C4’-H), 5.13 (brs, 1H, C3-H), 3.98 (dd, J= 4.4 Hz, J= 
7.8 Hz, 1H, C7’-H), 3.27 (dd, J= 6.0 Hz, J= 8.0 Hz, 1H, C9’-Ha), 2.99 (dd, J= 8.0 Hz, J= 14.0 
Hz, 1H, C9’-Hb), 2.66 (d, J= 13.4 Hz, 1H, C11- Ha), 2.30 (d, J= 14.0 Hz, 1H, C11- Hb), 1.54 (s, 
3H, C12-H), 1.01 (s, 3H, C13-H), 0.92 (d, J= 6.2 Hz, 3H, C14-H), 0.82 (s, 3H, C15-H); 
13
C 
NMR (50 MHz, CD3OD): δ 187.1 (C5’), 184.3 (C2’), 176.8 (C8’), 148.0 (C3’), 145.0 (C4), 
143.8 (C1’), 140.5 (C6’), 138.7 (C10’), 130.5 (C11’, C15’), 129.4 (C12’, C14’), 127.6 (C13’), 
121.8 (C3), 97.5 (C4’), 59.9 (C7’), signal overlapped with solvent signal (C10), 43.0 (C9), 39.5 
(C5), 39.0 (C9’), 37.5 (C8), 37.4 (C6), 35.6 (C11), 28.4 (C7), 27.5 (C2), 20.5 (C1), 20.3 (C13), 
18.4 (C14), 18.1 (C12), 17.0 (C15); IR (KBr, cm
-1
): 3365.2, 3026.4, 2957.0, 2929.6, 2857.3, 
1670.0, 1631.9, 1581.7, 1514.3, 1494.2, 1440.9, 1409.8, 1341.5, 1288.9, 1127.5, 1028.9; CIMS 
(MeOH): 476.27878 [M+1]
+; UV/Vis (MeOH): λmax (log ε) 286 (4.66), 496 (4.26).  
4.1.1.9. N-[3-[[(1R,2S,4aS,8aS)-1,2,3,4,4a,7,8,8a-octahydro-1,2,4a,5-tetramethyl-1-
naphthalenyl)methyl]-2,5-dioxo-1,4-cyclohexadien-1-yl]-(S)tryptophan (1i)  
Obtained by the same procedure as 1a, using 100 mg avarone and 98 mg L-tryptophan, 
but the color changed from yellow to red-purple and the reaction time was shortened to 3 h. For 
  
the first preparative TLC, eluent toluene/ethyl acetate (9:1) was used. 1i: red crystals; 52 mg 
(yield 32 %). Mp: 157–160 ºC (dec.); [α]D
20 
= –32 (c 0.125, CH3OH); 
1
H NMR (200 MHz, 
CD3OD): δ 7.55 (d, J= 7.2 Hz, 1H, C16’-H), 7.30 (d, J= 8.0 Hz, 1H, C13’-H), 7.09 (s, 1H, C11’-
H), 7.05-6.92 (m, 2H, C14’-H, C15’-H), 6.23 (brs, 1H, C6’-H), 5.27 (brs, 1H, C4’-H), 5.07 
(brs, 1H, C3-H), 4.09 (brs, 1H, C7’-H), 3.55-3.40 (brm, 1H, C9’-Ha), 3.30-3.15 (brm, 1H, C9’-
Hb), 2.55 (d, J= 13.4 Hz, 1H, C11- Ha), 2.28 (d, J= 13.4 Hz, 1H, C11- Hb), 1.52 (s, 3H, C12-H), 
0.99 (s, 3H, C13-H), 0.88 (d, J= 6.2 Hz, 3H, C14-H), 0.80 (s, 3H, C15-H); 
13
C NMR (50 MHz, 
CD3OD): δ 187.0 (C5’), 184.1 (C2’), 179.8 (C8’), 148.1 (C3’), 144.5 (C4), 143.4 (C1’), 140.4 
(C6’), 137.7 (C12’), 128.8 (C17’), 124.3 (C11’), 122.2 (C16’), 121.7 (C3), 119.8 (C15’), 119.2 
(C14’), 112.1 (C13’), 111.2 (C10’), 97.5 (C4’), 54.5 (C7’), signal overlapped with solvent signal 
(C10), 42.8 (C9), 39.3 (C5), 37.4 (C8), 37.0 (C6), 35.7 (C11), 28.8 (C9’), 28.3 (C7), 27.2 (C2), 
20.4 (C1), 20.1 (C13), 18.3 (C14), 18.1 (C12), 17.0 (C15); IR (KBr, cm
-1
): 3351.8, 2956.1, 
2839.6, 1664.8, 1632.6, 1581.7, 1439.9, 1412.7, 1145.3, 1024.0, 740.7, 659.7, 637.6, 611.3; 
CIMS (MeOH): 515.28989 [M+1]
+; UV/Vis (MeOH): λmax (log ε) 282 (4.74), 290 (4.71), 396 
(3.82), 500 (4.10).  
4.1.1.10. N-(5-tert-Butyl-3,6-dioxo-1,4-cyclohexadien-1-yl)-glycine (2a)   
Glycine (324 mg) was dissolved in 100 ml of saturated solution of NaHCO3, and a few 
drops of aqueous solution of NaOH until pH 10 were added. Solution was added in portions to 
the 100 ml of ethanol solution of tert-butylquinone (180 mg) and the color changed from yellow 
to red. The reaction mixture was stirred for 2.5h at room temperature. After ethanol had been 
removed, the remaining aqueous solution was extracted with ethyl acetate. Thereafter aqueous 
layer was acidified with 10% HCl and again extracted with ethyl acetate. The solutions were 
dried over anhydrous Na2SO4. After the evaporation of ethyl acetate, the product was purified by 
preparative TLC (silica gel GF254, 1 mm, chloroform/methanol (9:1)) and rechromatographed 
with the same eluent. The product was recrystallized in dichloromethane overnight, affording 2a 
as red crystals (31 mg; yield 12 %). Mp: 104–106 ºC (dec.); 1H NMR (200 MHz, CD3OD): δ 
6.41 (d, J=2.2 Hz, 1H, C6-H), 5.30 (d, J= 2.2 Hz, 1H, C4-H), 3.64 (brs, 2H, C11-H), 1.27 (s, 
9H, C8-H, C9-H, C10-H); 
13
C NMR (50 MHz, CD3OD): δ 187.8 (C5), 183.9 (C2), 174.9 (C12), 
153.1 (C1), 149.7 (C3), 135.9 (C6), 97.0 (C4), 47.0 (C11), 35.7 (C7), 29.4 (C8, C9, C10); IR 
(KBr, cm
-1
): 3356.9, 2959.9, 2930.6, 2871.1, 1725.8, 1633.2, 1591.1, 1486.1, 1461.1, 1393.9, 
  
1362.5, 1278.0, 1124.1, 1074.2; CIMS (MeOH): 238.10636 [M+1]
+; UV/Vis (MeOH): λmax (log 
ε) 274 (4.60), 368 (3.90), 476 (3.98).  
4.1.1.11. N-(5-tert-Butyl-3,6-dioxo-1,4-cyclohexadien-1-yl)-L-alanine (2b)  
Obtained by the same procedure as 2a, using 200 mg tert-butylquinone and 170 mg L-
alanine, but without adding of aqueous solution of NaOH. The reaction time was prolonged to 3 
h. For product purification by preparative TLC (silica gel GF254, 1 mm), chloroform/methanol 
(8:2) was used as the eluent. Compound 2b was obtained as red crystals (73 mg; yield 24 %). 
Mp: 159–163 ºC (dec.); [α]D
20 
= –32 (c 0.125, CH3OH); 
1
H NMR (200 MHz, CD3OD): δ 6.40 (d, 
J=2.2 Hz, 1H, C6-H), 5.35 (d, J= 2.2 Hz, 1H, C4-H), 3.81 (q, J= 6.8 Hz, 1H, C11-H), 1.43 (d, J= 
7.2 Hz, 3H, C13-H), 1.26 (s, 9H, C8-H, C9-H, C10-H); 
13
C NMR (50 MHz, CD3OD): δ 187.7 
(C5), 184.0 (C2), 179.3 (C12), 153.1 (C1), 148.8 (C3), 135.9 (C6), 97.0 (C4), 54.0 (C11), 35.7 
(C7), 29.4 (C8, C9, C10), 18.0 (C13); IR (KBr, cm
-1
): 3351.9, 2961.3, 1673.1, 1630.3, 1580.8, 
1488.0, 1455.2, 1416.4, 1365.3, 1338.6, 1283.0, 1171.5; CIMS (MeOH): 252.12285 [M+1]
+
; 
UV/Vis (MeOH): λmax (log ε) 274 (4.87), 486 (4.40).  
4.1.1.12. N-(4-tert-Butyl-3,6-dioxo-1,4-cyclohexadien-1-yl)-β-alanine (2c)  
Obtained by the same procedure as 2a, using 100 mg tert-butylquinone and 110 mg β-
alanine and the reaction time was prolonged to 3 h. Rechromatography was not necessary. 2c: 
red crystals; 74 mg (yield 48 %). Mp: 117–120 ºC; 1H NMR (200 MHz, CD3OD): δ 6.41 (brs, 
1H, C6-H), 5.44 (brs, 1H, C4-H), 3.30 (t, J= 1.6 Hz, 2H, C11-H), 2.55 (broad signal, 2H, C12-
H), 1.25 (s, 9H, C8-H, C9-H, C10-H); 
13
C NMR (50 MHz, CD3OD): δ 187.7 (C5), 184.0 (C2), 
178.1 (C13), 153.1 (C1), 150.1 (C3), 135.9 (C6), 96.6 (C4), 40.4 (C11), 35.7 (C7), 30.0 (C12) 
29.4 (C8, C9, C10); IR (KBr, cm
-1
): 3349.5, 2960.8, 1673.4, 1631.6, 1582.2, 1509.9, 1455.5, 
1365.4, 1256.1, 1158.3; CIMS (MeOH): 252.12255 [M+1]
+; UV/Vis (MeOH): λmax (log ε) 274 
(4.92), 484 (4.44).  
4.1.1.13. N-(5-tert-Butyl-3,6-dioxo-1,4-cyclohexadien-1-yl)-D-valine (2d)  
Obtained by the same procedure as 2a, using 130 mg tert-butylquinone and 140 mg D-valine. 
The crude product was purified by preparative TLC (silica gel GF254, 1 mm) using toluene/ethyl 
acetate (9:1) as the eluent. Compound 2d was obtained as red crystals (61 mg; yield 28 %). Mp: 
  
180–183 ºC (dec.); [α]D
20 
= –20 (c 0.250, CH3OH); 
1
H NMR (200 MHz, CD3OD): δ 6.41 (d, J= 
2.4 Hz, 1H, C6-H), 5.40 (d, J= 2.4 Hz, 1H, C4-H), 3.61 (d, J= 6.2 Hz, 1H, C11-H), 2.20 (m, 1H, 
C13-H), 1.26 (s, 9H, C8-H, C9-H, C10-H), 0.98 (d, J= 6.4 Hz, 6H, C14-H, C15-H); 
13
C NMR 
(50 MHz, CD3OD): δ 187.8 (C5), 184.0 (C2), 177.6 (C12), 153.0 (C1), 149.6 (C3), 135.9 (C6), 
97.2 (C4), 64.5 (C11), 35.7 (C7), 32.5 (C13) 29.4 (C8, C9, C10), 20.0 (C15), 19.1 (C14); IR 
(KBr, cm
-1
): 3350.0, 2962.7, 2873.6, 1673.5, 1630.7, 1578.5, 1506.2, 1421.1, 1340.7, 1162.2; 
CIMS (MeOH): 280.15442 [M+1]
+; UV/Vis (MeOH): λmax (log ε) 274 (4.78), 490 (4.34).  
4.1.1.14. N-(5-tert-Butyl-3,6-dioxo-1,4-cyclohexadien-1-yl)-L-leucine (2e)  
Obtained by the same procedure as 2a, but the color changed from yellow to red-purple 
and the reaction time was shortened to 2 h. For the first purification by preparative TLC 
toluene/ethyl acetate (9:1) was used as the eluent. Starting from 100 mg tert-butylquinone and 80 
mg L-leucine, 2e was obtained as red crystals (32 mg; yield 18 %). Mp: 147–148 ºC; [α]D
20 
= –20 
(c 0.250, CH3OH); 
1
H NMR (200 MHz, CD3OD): δ 6.32 (d, J= 2.2 Hz, 1H, C6-H), 5.29 (d, J= 
2.2 Hz, 1H, C4-H), 3.68 (m, 1H, C11-H), 1.64 (m, 3H, C13-H, C14-H), 1.18 (s, 9H, C8-H, C9-
H, C10-H), 0.89 (d, J= 6.0 Hz, 3H, C15-H), 0.83 (d, J= 6.0 Hz, 3H, C16-H); 
13
C NMR (50 
MHz, CD3OD): δ 187.8 (C5), 184.0 (C2), 178.4 (C12), 153.1 (C1), 149.4 (C3), 135.9 (C6), 97.0 
(C4), 58.0 (C11), 42.3 (C13), 35.7 (C7), 29.4 (C8, C9, C10), 26.4 (C14), 23.4 (C15), 22.7 
(C16); IR (KBr, cm
-1
): 3359.8, 2958.5, 2871.7, 1672.3, 1630.8, 1578.7, 1511.2, 1419.7, 1365.0, 
1341.6, 1264.7, 1165.1; CIMS (MeOH): 294.16991 [M+1]
+; UV/Vis (MeOH): λmax (log ε) 272 
(4.72), 488 (4.258).  
4.1.1.15. N-(4-tert-Butyl-3,6-dioxo-1,4-cyclohexadien-1-yl)-L-proline (2f)  
Obtained by the same procedure as 2a, using 200 mg tert-butylquinone and 280 mg L-
proline. The color changed from yellow to red-purple and the reaction time was prolonged to 3 h. 
The product was rechromatographed by preparative TLC using toluene/ethyl acetate (6:4). 2f: 
purple crystals; 29 mg (yield 9 %). Mp: 148–152 ºC (dec.); [α]D
20 
= –264 (c 0.125, CH3OH); 
1
H 
NMR (200 MHz, CD3OD): δ 6.28 (s, 1H, C6-H), 5.40 (s, 1H, C3-H), 3.63 (poorly resolved dd 
overlapping with C15-H, 1H, C11-H), 3.55-3.40 (m, 2H, C15-H), 2.24-2.12 (m, 2H, C13-H), 
1.90 (brs, 2H, C14-H), 1.26 (s, 9H, C8-H, C9-H, C10-H); 
13
C NMR (50 MHz, CD3OD): δ 187.1 
(C2), 187.0 (C5), 180.1 (C12), 158.6 (C1), 148.7 (C4), 129.8 (C6), 104.6 (C3), 66.7 (C11), 52.2 
  
(C15), 36.0 (C7), 33.0 (C13), 29.9 (C8, C9, C10), 24.0 (C14); IR (KBr, cm
-1
): 3377.2, 2962.2, 
1623.5, 1581.5, 1424.5, 1146.2; CIMS (MeOH): 278.13828 [M+1]
+; UV/Vis (MeOH): λmax (log 
ε) 276 (4.62), 498 (4.11).  
4.1.1.16. N-(5-tert-Butyl-3,6-dioxo-1,4-cyclohexadien-1-yl)-L-methionine (2g)  
Obtained by the same procedure as 2a, using 130 mg tert-butylquinone and 118 mg L-
methionine, but the reaction time was shortened to 2 h and extraction was done with chloroform. 
2g: red crystals; 43 mg (yield 17 %). Mp: 137–139 ºC (dec.); [α]D
20 
= –24 (c 0.125, CH3OH); 
1
H 
NMR (200 MHz, CD3OD): δ 6.42 (d, J= 2.2 Hz, 1H, C6-H), 5.44 (d, J= 2.2 Hz, 1H, C4-H), 3.88 
( dd, J= 6.2 Hz, J= 11.8 Hz, 1H, C11-H), 2.52 (m, 2H, C14-H), 2.15-2.01 (m, 2H, C13-H), 1.98 
(s, 3H, C15-H), 1.27 (s, 9H, C8-H, C9-H, C10-H); 
13
C NMR (50 MHz, CD3OD): δ 187.8 (C5), 
184.0 (C2), 177.0 (C12), 153.2 (C1), 149.2 (C3), 135.8 (C6), 97.2 (C4), 58.0 (C11), 35.7 (C7), 
32.5 (C13), 31.2 (C14), 29.4 (C8, C9, C10), 15.3 (C15); IR (KBr, cm
-1
): 3344.6, 2961.2, 
1671.4, 1630.4, 1580.6, 1488.2, 1423.6, 1339.5, 1143.7; CIMS (MeOH): 312.12628 [M+1]
+
; 
UV/Vis (MeOH): λmax (log ε) 274 (4.77), 486 (4.31). 
4.1.1.17. N-(5-tert-Butyl-3,6-dioxo-1,4-cyclohexadien-1-yl)-L-phenylalanine (2h)  
Obtained by the same procedure as 2a, using 230 mg tert-butylquinone and 232 mg L-
phenilalanine. The reaction time was prolonged to 3 h. The product was rechromatographed by 
preparative TLC using toluene/ethyl acetate (9:1) as the eluent. 2h: red crystals (186 mg, yield 
41 %). Mp: 143–146 ºC; [α]D
20 
= 16 (c 0.250, CH3OH); 
1
H NMR (200 MHz, CD3OD): δ 7.22-
7.14 (m, 5H, C15, C16, C17, C18, C19), 6.35 (d, J= 2.5 Hz, 1H, C6-H), 5.26 (d, J= 2.5 Hz, 1H, 
C4-H), 3.99 (dd, J=5.0 Hz, J= 7.4 Hz, 1H, C11-H),  3.23 (m, 1H, C13-Ha), 3.05 (dd, J= 7.2 Hz, 
J= 13.4 Hz, 1H, C13-Hb), 1.22 (s, 9H, C8-H, C9-H, C10-H); 
13
C NMR (50 MHz, CD3OD): δ 
187.8 (C5), 183.8 (C2), 177.0 (C12), 153.0 (C1), 149.0 (C3), 138.8 (C14), 135.7 (C6), 130.5 
(C15, C19), 129.4 (C16, C18), 127.7 (C17), 97.2 (C4), 60.1 (C11), 38.8 (C13), 35.6 (C7), 29.4 
(C8, C9, C10); IR (KBr, cm
-1
): 3353.7, 3060.6, 3027.9, 2960.2, 2870.3, 1672.5, 1627.9, 1573.3, 
1502.0, 1449.9, 1400.6, 1365.3, 1340.8, 1256.6; CIMS (MeOH): 328.15398 [M+1]
+
; UV/Vis 
(MeOH): λmax (log ε) 274 (4.71), 488 (4.29). 
4.1.1.18. N-(5-tert-Butyl-3,6-dioxo-1,4-cyclohexadien-1-yl)-L-tryptophan (2i)  
  
Obtained by the same procedure as 2a, but the reaction time was shortened to 1 h and the 
product was purified by preparative TLC using toluene/ethyl acetate (9:1) as the eluent. Starting 
from 100 mg tert-butylquinone and 125 mg L-tryptophane, 2i was obtained as red crystals (42 
mg, yield 18 %). Mp: 156–159 ºC (dec.); [α]D
20 
= –24 (c 0.125, CH3OH); 
1
H NMR (200 MHz, 
CD3OD): δ 7.56 (d, J= 8.0 Hz, 1H, C12-H), 7.30 (d, J= 8.0 Hz, 1H, C17-H), 7.13 (s, 1H, C15-
H), 7.08-6.90 (m, 2H, C18-H, C19-H), 6.34 (d, J= 2.0 Hz, 1H, C6-H), 5.31 (poorly resolved d, 
1H, C4-H), 4.11 (poorly resolved dd, 1H, C11-H), 3.49 (dd, J= 4.2 Hz, J= 14.4 Hz, 1H, C13-
Ha), 3.27 (dd, J= 7.2 Hz, J= 14.4 Hz, 1H, C13-Hb), 1.18 (s, 9H, C8-H, C9-H, C10-H); 
13
C NMR 
(50 MHz, CD3OD): δ 187.7 (C5), 183.6 (C2), 177.6 (C12), 152.8 (C1), 149.1 (C3), 138.0 (C16), 
135.7 (C6), 129.1 (C21), 124.5 (C15), 122.2 (C20), 119.7 (C19), 119.4 (C18), 112.2 (C17), 
111.4 (C14), 96.9 (C4), 59.8 (C11), 35.5 (C7), 29.3 (C8, C9, C10), 28.8 (C13); IR (KBr, cm
-1
): 
3349.4, 3001.7, 2960.7, 2871.7, 1671.5, 1630.7, 1574.9, 1501.2, 1421.7, 1363.3, 1341.5, 1151.4; 
CIMS (MeOH): 367.16471 [M+1]
+; UV/Vis (MeOH): λmax (log ε) 278 (4.90), 496 (4.27).  
4.2. Pharmacology 
4.2.1. Antiproliferative activity 
4.2.1.1. Compounds and solutions 
Stock solutions of investigated complexes, were prepared in DMSO at concentrations of 
10 mM and afterwards they were diluted with complete nutrient medium (RPMI-1640 without 
phenol red) supplemented with 3 mM L-glutamine, 100 µg/mL streptomycin, 100 IU/mL 
penicillin, 10 % heat inactivated fetal bovine serum (FBS), and 25 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (Hepes) adjusted to pH 7.2 by bicarbonate solution. RPMI-1640, 
FBS, Hepes and L-glutamine were products of Sigma Chemical Co., St. Louis, MO. The MTT 
(2-(4,5-dimethylthiazol-2-yl)-3,5-diphenyl-2H-tetrazolium bromide) was dissolved (5 mg/ml) in 
phosphate buffer saline pH 7.2 and filtered (0.22 µm) before use. The RPMI 1640 cell culture 
medium, fetal bovine serum (FBS), and MTT, were purchased from Sigma Chemical Company, 
USA. 
4.2.1.2. Cell lines 
  
Cervix adenocarcinoma cell line (HeLa), human melanoma (Fem-X), human chronic 
myelogenous leukemia (K562) cells, human breast cancer (MDA-MB-453), non-small cell lung 
carcinoma (A549) and a non-cancerous cell line, MRC-5 (human embryonic lung fibroblast) 
were grown in RPMI-1640 medium (Sigma). Media were supplemented with 10 % fetal bovine 
serum, L-glutamine, and penicillin—streptomycin (Sigma). 
4.2.1.3. Treatment of cell lines 
Stock solutions (10 mM) of compounds, made in dimethyl sulfoxide (DMSO), were 
dissolved in corresponding medium to the required working concentrations. Neoplastic cells 
HeLa (2000 cells per well), Fem-X (5000 cells per well), K562 (5000 cells per well), MDA-MB-
453 (3000 cells per well), A549 (5000 cells per well), and non-cancerous MRC-5 (5000 cells per 
well) were seeded into wells of a 96-well flat-bottomed microtitre plates, and 24 h later, after the 
cell adherence, five different, double diluted, concentrations of investigated compounds were 
added to the wells. Exceptionally, compounds were applied to the suspension of leukemia K562 
cells (5000 cells per well), 2 hours after the cell seeding. Final concentrations applied to target 
cells were 200, 100, 50, 25, and 12.5 μM, except to the control wells where only nutrient 
medium was added to the cells. Nutrient medium was RPMI 1640 medium, supplemented with 
L-glutamine (3 mM), streptomycin (100 µg/ml), and penicillin (100 IU/ml), 10 % heat 
inactivated (56 ˚C) fetal bovine serum (FBS) and 25 mM Hepes, and was adjusted to pH 7.2 by 
bicarbonate solution. The cultures were incubated for 72 h.  
4.2.1.4. Determination of cell survival 
 The effect of the prepared compounds on cancer cell survival was determined by the 
microculture tetrazolium test (MTT) according to Mosmann [47] with modification by Ohno and 
Abe [48] 72 h after addition of the compounds, as described earlier. Briefly, 20 mL of MTT 
solution (5 mg/mL phosphate-buffered saline) was added to each well. Samples were incubated 
for a further 4 h at 37 ºC in a humidified atmosphere of 95 % air/5 % CO2 (v/v). Then, 100 mL 
of 100 g/L sodium dodecyl sulfate were added to the extract, resulting in formation of insoluble 
formazan by conversion of the MTT dye by viable cells. The number of viable cells in each well 
was proportional to the intensity of the absorbance of light, which was read in an enzyme-linked 
immunosorbent assay (ELISA) plate reader at 570 nm. The absorbance (A) at 570 nm was 
  
measured 24 h later. To determine cell survival (%), A of the sample with cells grown in the 
presence of various concentrations of the investigated compounds was divided by the control 
optical density (A of control cells grown only in nutrient medium) and multiplied by 100. It was 
implied that A of the blank was always subtracted from A of the corresponding sample with 
target cells. IC50 was defined as the concentration of an agent inhibiting cell survival by 50 % 
compared with a vehicle-treated control. As positive controls, cis-diamminedichloroplatinum 
(cis-DDP, cisplatin) was used. All experiments were done in triplicate. 
4.2.1.5. Cell cycle analysis 
Cervix adenocarcinoma cell line (HeLa) was seeded in six-well plates (3 × 10
5
 
cells/well), and after 24 h treated with investigated compounds, except control cells, and 
incubated at 37 °C for the next 24 hours. Concentrations used corresponded to IC50 values. After 
the incubation, the cells were collected by trypsinization, and fixed in ice-cold 70 % ethanol for 
1h on ice, then at −20 °C for at least a week. After fixation, the cells were washed in PBS and 
pellets obtained by centrifugation were treated with RNase (100 μg/mL) at 37 °C for 30 min and 
then incubated with propidium iodide (PI) (40 μg/mL) for at least 30 min. DNA content and cell-
cycle distribution were analyzed using a Becton Dickinson FACSCalibur flow cytometer. Flow 
cytometry analysis was performed using CellQuestR (Becton Dickinson, San Jose, CA, USA) 
software on a minimum of 10,000 cells per sample [49]. 
4.2.1.6. Determination of target caspases 
In order to examine the role of caspases involved in the apoptotic cell death induced by 
the investigated compounds, the percentages of HeLa cells pretreated with caspase inhibitors in 
sub-G1 phase were determined. HeLa cells were preincubated for 2 h with specific caspase 
inhibitors (final concentration e 40 mM): Z-DEVD-FMK (caspase-3 inhibitor), Z-IETD-FMK 
(caspase-8 inhibitor) and Z-LEHD-FMK (caspase-9 inhibitor). Caspase inhibitors were 
purchased from R&D Systems (Minneapolis, USA). The tested compounds were applied to 
target HeLa cells at concentrations which corresponded to 2IC50 values obtained for 72 h. For 
each compound, one sample of HeLa cells was not treated with inhibitor and served as a referent 
sample. After 24 h of incubation, cells were harvested and fixed in 70 % ethanol on ice. Samples 
were stored at –20 ºC for one week before PI staining. Changes in the percentages of cells in sub-
  
G1 phase were determined using a FACSCalibur Flow Cytometer and analyzed using CellQuest 
Software. 
4.2.2. Antibacterial activity 
A microbroth double dilution test [50] was used to determine antibacterial activity of 
compounds against six Gram-positive bacteria: Staphylococcus aureus (ATCC 6538), 
Micrococcus flavus (ATCC 10240), Micrococcus luteus (ATCC 4698), Clostridium sporogenes 
(ATCC 19404), Kocuria rhizophila (ATCC 9341), Bacillus subtilis (ATCC 6633), and four 
Gram-negative bacteria: Escherichia coli (ATCC 25922), Proteus hauseri (ATCC 13315), 
Salmonella enterica (ATCC 13076), Pseudomonas aeruginosa (ATCC 9027). Sterile 96-well 
polystyrene microliter plates with well capacities of 300 µL were used, and 100 µL of fresh 
Mueller Hinton broth were added to each well of the plate. One hundred microliters of the 
compound stock solution (10 mg/mL) were added to the first well of the each row. Then, 100 µL 
of the solution were removed from the first well of the row to the following well of the same row 
and mixed with the broth previously added to it. This double dilution was done in every row of 
the plate. One row was used as a positive control containing a broad-spectrum antibiotic 
amikacin to determine the sensitivity of a bacterial strain. The other row contained the DMSO as 
a negative control. Afterwards, every well was inoculated with 10 µL (10
6
 cells per mL) of 
bacterial cultures. The microtiter plate was incubated at 37 ºC for 24 h. The growth of bacteria 
was measured. The lowest concentration of tested compound which inhibited the bacterial 
growth was defined as MIC.  
4.2.3. Antifungal activity 
The tested fungi were Candida albicans (ATCC 10231), Saccharomyces cerevisiae 
(ATCC 9763) and Aspergillus brasiliensis (ATCC 16404). Antifungal activities of the 
synthesized compounds were evaluated as previously described for antibacterial activity, by a 
microbroth double dilution assay. In this test the used broth was Sabouraud dextrose broth and 
each well was inoculated with 10 µL of fungal cultures (10
5
 spores per mL). The microliter plate 
was incubated at 28 ºC for 48 h. The MIC was determined as the lowest concentration that 
resulted in inhibition of fungal growth.   
4.2.4. The brine shrimp test  
  
A small bag (18 g) of lyophilized eggs of brine shrimp Artemia salina was added to 0.5 L 
of tap water. A few grains of dried yeast were stirred in, and air was passed through the 
suspension where the temperature was maintained at 18–20 ºC under illumination for 48 h. 
Freshly hatched nauplii were used in further experiments [51].  
All derivatives were dissolved in DMSO and various amounts (0.01–1 mg) were added to 
950 µL of artificial seawater with 10–20 nauplii. The final concentration of DMSO was 5 %. 
After 24 h illumination at room temperature, the number of dead and surviving nauplii were 
counted and statistically analyzed. LC50 was defined as a concentration lethal to 50 % of the 
nauplii. All samples were done in triplicate. 
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Figure captions 
 
Fig. 1. Sesquiterpene quinones with an amino acid in side chain (nakijiquinones A–D; 
smenospongines B and C) 
Fig. 2. Chemical structure of avarone and tert–butylquinone derivatives 
Fig. 3. Tautomeric forms of avarone and tert-butylquinone derivatives 
Fig. 4. Cyclic voltammogram of compounds 1, 1i, 2 and 2i 
Fig. 5. Cell cycle distribution after 24 h continuous action of investigated compounds. 
Concentration corresponded to IC50. 
Fig. 6. Cell cycle distribution after 24 h continuous action of investigated compounds. 
Concentration corresponded to 2IC50. 
Fig. 7. Influence of compounds 1c (A) and 1e (B) alone or in combination with inhibitors of 
caspase-3 (Z-DEVD-FMK), caspase-8 (Z-IETD-FMK) or caspase-9 (Z-LEHD-FMK) on the 
fraction of HeLa cells in sub-G1 phase. 
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